Cargando…

Correlation of Anticancer Drug Prices with Outcomes of Overall Survival and Progression-Free Survival in Clinical Trials in Japan

Drug pricing methods vary extensively across countries. Japan calculates drug prices using cost accounting and based on the efficacy of similar drugs. This study investigated the relationship between drug prices and their clinical efficacy and usefulness using public information on anticancer drugs...

Descripción completa

Detalles Bibliográficos
Autores principales:	Okabe, Ayano, Hayashi, Haruto, Maeda, Hideki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9955512/ https://www.ncbi.nlm.nih.gov/pubmed/36826098 http://dx.doi.org/10.3390/curroncol30020137

Ejemplares similares

Relationships between developmental strategies for additional indications and price revisions for anticancer drugs in Japan
por: Maeda, Hideki, et al.
Publicado: (2021)

Systematic Review and Meta-Analysis of Correlation of Progression-Free Survival-2 and Overall Survival in Solid Tumors
por: Chowdhury, Simon, et al.
Publicado: (2020)

Progression-free or overall survival…revisited in BOLERO-2
por: Gupta, Sudeep
Publicado: (2014)

Correlation between treatment effects on response rate and progression-free survival and overall survival in trials of targeted therapies in molecularly enriched populations
por: Solomon, B.J., et al.
Publicado: (2022)

Progression-free survival as a potential surrogate for overall survival in metastatic breast cancer
por: Beauchemin, Catherine, et al.
Publicado: (2014)

Prognostic Factors of Atypical Meningioma: Overall Survival Rate and Progression Free Survival Rate
por: Lee, Jae Ho, et al.
Publicado: (2017)

Quantifying the association between progression‐free survival and overall survival in oncology trials using Kendall's τ
por: Weber, Enya M., et al.
Publicado: (2018)

Progression-free survival as a surrogate for overall survival in oncology trials: a methodological systematic review
por: Belin, Lisa, et al.
Publicado: (2020)

Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic colorectal cancer
por: Cicero, Giuseppe, et al.
Publicado: (2018)

Relationship between Progression-free Survival and Overall Survival in Randomized Clinical Trials of Targeted and Biologic Agents in Oncology
por: Hess, Lisa M, et al.
Publicado: (2019)

Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials
por: Wang, Zi-Xian, et al.
Publicado: (2021)

Nicotinamide N-methyltransferase is overexpressed in prostate cancer and correlates with prolonged progression-free and overall survival times
por: ZHOU, WEIMIN, et al.
Publicado: (2014)

Prognostic factors for progression‐free and overall survival in malignant pleural mesothelioma
por: Guzmán‐Casta, Jordi, et al.
Publicado: (2021)

Correlation between progression-free survival and overall survival in patients with ovarian cancer after cytoreductive surgery: a systematic literature review
por: Chase, Dana M, et al.
Publicado: (2023)

Evaluating relapse-free survival as an endpoint for overall survival in adjuvant immunotherapy trials
por: Li, Yuanfang, et al.
Publicado: (2023)

Interpretation of meta-analysis evaluating progression-free survival as a surrogate endpoint for overall survival in glioblastoma
por: Han, Kelong, et al.
Publicado: (2015)

Prognostic nomogram that predicts progression-free survival and overall survival of patients with ovarian clear cell carcinoma
por: Li, Jiayi, et al.
Publicado: (2022)

Glioblastoma: A Retrospective Analysis of the Role of the Maximal Surgical Resection on Overall Survival and Progression Free Survival
por: Polonara, Gabriele, et al.
Publicado: (2023)

Progression-free survival as a surrogate endpoint for overall survival in modern ovarian cancer trials: a meta-analysis
por: Sjoquist, Katrin M., et al.
Publicado: (2018)

Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma
por: Cabibbo, Giuseppe, et al.
Publicado: (2020)

Progression-free survival, post-progression survival, and tumor response as surrogate markers for overall survival in patients with extensive small cell lung cancer
por: Imai, Hisao, et al.
Publicado: (2015)

Magnetic resonance spectroscopic correlates of progression free and overall survival in “glioblastoma, IDH-wildtype, WHO grade-4”
por: Sacli-Bilmez, Banu, et al.
Publicado: (2023)

Replication of Overall Survival, Progression-Free Survival, and Overall Response in Chemotherapy Arms of Non–Small Cell Lung Cancer Trials Using Real-World Data
por: Ton, Thanh G.N., et al.
Publicado: (2022)

Searching for potential surrogate endpoints of overall survival in clinical trials for patients with prostate cancer
por: Maeda, Hideki, et al.
Publicado: (2021)

Progression-free survival/time to progression as a potential surrogate for overall survival in HR+, HER2− metastatic breast cancer
por: Forsythe, Anna, et al.
Publicado: (2018)

A correlation analysis to assess event-free survival as a trial-level surrogate for overall survival in early breast cancer
por: Gyawali, Bishal, et al.
Publicado: (2021)

Immunoparesis in newly diagnosed Multiple Myeloma patients: Effects on overall survival and progression free survival in the Danish population
por: Sørrig, Rasmus, et al.
Publicado: (2017)

ECOG is as independent predictor of the response to chemotherapy, overall survival and progression-free survival in carcinoma of unknown primary site
por: Grajales-Álvarez, Rocío, et al.
Publicado: (2017)

Therapeutic effect of apatinib on overall survival is mediated by prolonged progression-free survival in advanced gastric cancer patients
por: Huang, Lihong, et al.
Publicado: (2016)

The Overall Survival and Progression-Free Survival in Patients with Advanced Adrenocortical Cancer Is Increased after the Multidisciplinary Team Evaluation
por: Tizianel, Irene, et al.
Publicado: (2022)

Correlation between pathologic complete response, event-free survival/disease-free survival and overall survival in neoadjuvant and/or adjuvant HR+/HER2-breast cancer
por: Gogate, Anagha, et al.
Publicado: (2023)

The expression of Eps15 homology domain 1 is negatively correlated with disease-free survival and overall survival of osteosarcoma patients
por: Yu, Hongwei, et al.
Publicado: (2019)

Metabolic Parameters as Predictors for Progression Free and Overall Survival of Patients with Metastatic Colorectal Cancer
por: Nemeth, Zsuzsanna, et al.
Publicado: (2020)

Low plateletcrit is associated with reduced progression: Free and overall survival in chronic lymphocytic leukemia
por: Ozbalci, Demircan, et al.
Publicado: (2023)

Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials
por: Han, Kelong, et al.
Publicado: (2014)

Soluble VE-cadherin in metastatic breast cancer: an independent prognostic factor for both progression-free survival and overall survival
por: Rochefort, Pauline, et al.
Publicado: (2017)

KAT6A amplifications are associated with shorter progression-free survival and overall survival in patients with endometrial serous carcinoma
por: Saglam, Ozlen, et al.
Publicado: (2020)

Machine learning classifiers for predicting 3-year progression-free survival and overall survival in patients with gliomas after surgery
por: Zhang, Bin, et al.
Publicado: (2021)

Prognostic significance of sarcopenia diagnosed based on the anthropometric equation for progression-free survival and overall survival in patients with colorectal cancer
por: Xie, Hailun, et al.
Publicado: (2023)

Association of progression-free or event-free survival with overall survival in diffuse large B-cell lymphoma after immunochemotherapy: a systematic review
por: Zhu, Jie, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_1tc80si4rgmodolaejlngpb22s